MYC and neoplasm: The improved T cell-stimulatory capacity of λ-MYC TIDCs detected in vitro (Fig. 4), which was also seen in an HPV16 tumor model after anti-PD1/anti-CTLA-4 treatment [35], may be due to the altered cytokine expression pattern, but other mechanisms cannot be precluded.